Description: New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Home Page: ir.newhorizonbio.com
T1 Building
Hangzhou,
310052
China
Phone:
86 57 1811 07210
Officers
| Name | Title |
|---|---|
| Mr. Yeqing Zhu | CEO, Executive Chairman & Co-founder |
| Dr. Yiyou Chen Ph.D. | Executive Director & Chief Scientific Officer |
| Mr. Yu Gao | CFO & Joint Company Secretary |
| Dr. Ning Lu | Chief Technology Officer |
| Ms. Ming-Wai Mok | Joint Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8901 |
| Price-to-Sales TTM: | 0.5541 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1041 |